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Should women aged 70-74 be invited to participate in screening
mammography? A report on two Australian community juries
Abstract

Objective To elicit informed views from Australian women aged 70-74 regarding the acceptability of ceasing
to invite women their age to participate in government-funded mammography screening (BreastScreen).
Design Two community juries held in 2017. Setting Greater Sydney, a metropolis of 4.5 million people in
New South Wales, Australia. Participants 34 women aged 70-74 with no personal history of breast cancer,
recruited by random digit dialling and previously randomly recruited list-based samples. Main outcomes and
measures Jury verdict and rationale in response to structured questions. We transcribed audio-recorded jury
proceedings and identified central reasons for the jury's decision. Results The women's average age was 71.5
years. Participants were of diverse sociocultural backgrounds, with the sample designed to include women of
lower levels of educational attainment. Both juries concluded by majority verdict (16-2 and 10-6) that
BreastScreen should continue to send invitations and promote screening to their age group. Reasons given for
the majority position include: (1) sending the invitations shows that society still cares about older women,
empowers them to access preventive health services and recognises increasing and varied life expectancy; (2)
screening provides women with information that enables choice and (3) if experts cannot agree, the
conservative approach is to maintain the status quo until the evidence is clear. Reasons for the minority
position were the potential for harms through overdiagnosis and misallocation of scarce health resources.
Conclusions Preventive programmes such as mammography screening are likely to have significant symbolic
value once they are socially embedded. Arguments for programme de-implementation emphasising declining
benefit because of limited life expectancy and the risks of overdiagnosis seem unlikely to resonate with healthy
older women. In situations where there is no consensus among experts on the value of established screening
programmes, people may strongly prefer receiving information about their health and having the opportunity
make their own choices.
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Abstract
Objective To elicit informed views from Australian women
aged 70–74 regarding the acceptability of ceasing to invite
women their age to participate in government-funded
mammography screening (BreastScreen).
Design Two community juries held in 2017.
Setting Greater Sydney, a metropolis of 4.5 million people
in New South Wales, Australia.
Participants 34 women aged 70–74 with no personal
history of breast cancer, recruited by random digit
dialling and previously randomly recruited list-based
samples.
Main outcomes and measures Jury verdict and rationale
in response to structured questions. We transcribed audiorecorded jury proceedings and identified central reasons
for the jury’s decision.
Results The women’s average age was 71.5 years.
Participants were of diverse sociocultural backgrounds,
with the sample designed to include women of lower
levels of educational attainment. Both juries concluded
by majority verdict (16–2 and 10–6) that BreastScreen
should continue to send invitations and promote screening
to their age group. Reasons given for the majority position
include: (1) sending the invitations shows that society
still cares about older women, empowers them to access
preventive health services and recognises increasing and
varied life expectancy; (2) screening provides women
with information that enables choice and (3) if experts
cannot agree, the conservative approach is to maintain
the status quo until the evidence is clear. Reasons
for the minority position were the potential for harms
through overdiagnosis and misallocation of scarce health
resources.
Conclusions Preventive programmes such as
mammography screening are likely to have significant
symbolic value once they are socially embedded.
Arguments for programme de-implementation
emphasising declining benefit because of limited life
expectancy and the risks of overdiagnosis seem unlikely
to resonate with healthy older women. In situations where
there is no consensus among experts on the value of
established screening programmes, people may strongly
prefer receiving information about their health and having
the opportunity make their own choices.

Strengths and limitations of this study
►► Community juries are a deliberative method that

involves a process of iterative two-way exchange
of information between members of the public and
experts. By providing extensive information from a
range of experts, and ensuring conditions for reasonable and extended debate, community juries
elicit more considered judgements than other social
research methods such as surveys or focus groups.
►► Women aged 70–74 were asked to deliberate on a
well-defined question: whether they should be invited to participate in mammography screening.
►► Consensus was encouraged but not required; the
reasons jurors gave for their decision, and dissenting views and minority positions were also recorded.
►► The sample size was small, but this is an unavoidable characteristic of community jury methods and
is necessary for high-quality deliberation.
►► Results were clear and sustained across two juries,
therefore, it seems likely the findings are replicable
in women this age who have participated in screening for several decades.

Introduction
The appropriate age at which to cease
mammography
screening
remains
contested.1 2 Screening older women for
breast cancer is intuitively attractive as the
incidence of this condition increases with
age. But detecting a breast cancer early is not
always beneficial. Cancers detected in older
women are more likely to be slow growing,3
and breast cancer mortality as a proportion
of all-cause mortality decreases with age.4 At
the same time, the impacts and side effects
of breast cancer treatments for older women
are often exacerbated by concurrent disease
burdens.5 Although breast screening may
be beneficial for women aged 70 years and
older who expect to live at least another 10
years, this must be weighed against the risk
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Figure 1

2

to participate in mammography screening. Our aim was
to elicit the informed views of Australian women aged
70–74 as to the acceptability and perceived legitimacy of
continuing to invite women in this age group to the Australian mammography screening programme. Community
juries are an established, appropriate method to achieve
this.16 Unlike surveys and focus groups, the process
involves extensive provision of information, constructive,
structured dialogue between public and experts, and
adequate time for consideration.17 The method assumes
that people can think rationally and change their views
should the evidence warrant it.18 The process is like a
legal proceeding, but the outputs are not legally binding:
instead they provide evidence of public values and the
likely acceptability and perceived legitimacy of different
policy alternatives to assist policy-making.16 19
We consulted with major stakeholders (consumer
organisations, epidemiologists, women’s health physicians and the Cancer Council of Australia) to determine
the most appropriate questions for the community juries
to consider (figure 1). Because of continued uncertainty
as to the balance of benefits and harms of breast cancer
screening in older women, all stakeholders agreed that
the key issue to consider was whether BreastScreen
Australia should continue to invite women aged 70–74
to participate in its programme. Even though a further
change in policy is not currently being considered, the
results of this study could be used to inform discussion
and provision of information about overdiagnosis and
overtreatment of screen detected breast cancer in older
women and to inform future research on health communication. Additionally, the results may assist in developing policy in other jurisdictions where changes in the
target age group for breast cancer screening are being

The charge/question for the jury.
Degeling C, et al. BMJ Open 2018;8:e021174. doi:10.1136/bmjopen-2017-021174
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of harm due to false positives, overdiagnosis and the side
effects of treatment in cases of breast cancer that were
never going to cause clinical harm.2 The scientific data
relevant to mammography screening for women aged
70–74 is mixed and limited, and experts are divided as to
the balance of benefit and harm of continuing to screen
older age groups.6–8
The Australian breast cancer screening programme
(BreastScreen Australia) offers free biennial screening
to women over age 40. Since 1991, women aged 50–69
years have been specifically targeted via individual letters
of invitation. Until 2013, women older than 69 were
able to access free screening services if they chose, but
they did not receive biennial invitations and mammography screening was not actively promoted to them. In
July 2013, BreastScreen Australia extended the target
age group for breast screening by mammography from
50–69 years to 50–74 years. Supporting promotion and
marketing campaigns were implemented to encourage
women to participate.9 Participation by women aged over
70 in breast cancer screening has increased from just over
220 000 per annum to almost 270 000 as a consequence
of these changes.10 There have been significant tensions
in Australia over extending the target age for the BreastScreen programme,11–14 which have not been resolved
by evidence of benefit and harm. It is often proposed
that the solution is to give women the opportunity to
make an informed choice about whether to undergo
breast screening, supported by balanced, objective
information,6 15 but the complexity and relative paucity
of evidence on the effect of screening on this older age
group makes this task difficult.
We report on two community juries convened to
consider dilemmas raised by inviting women aged 70–74

Open access

Methods
Design and study setting
A community jury (similar to the proprietary method
citizens’ juries) is a group of citizens brought together
to receive detailed evidence about and deliberate on a
specific issue.19 Community juries have been used in
Australia and elsewhere to consider issues surrounding
cancer screening.20–22 Community juries are a deliberative method, with these general characteristics:
1. A group of citizens is convened for 1–3 days.
2. They are asked to consider a specific issue.
3. They hear evidence from (often opposed) experts,
and ask questions of those experts.
4. They are given time for deliberation, and to come to a
conclusion, which is documented.
There are two main approaches to community juries.
In the first, participants work as a group to draft open
sets of recommendations on an issue; in the second, jury
members vote on options presented by researchers.23 We
used a combined approach (figure 1). Both juries were
held over 2 days in May 2017 at the University of Sydney.
Participants and recruitment
We contracted an independent professional research
service to recruit two juries of women aged 70–74 living
in Greater Sydney, Australia from randomly generated
list-based samples and random digit dialling. We selected
women based on their sociodemographic characteristics,
as well as their eligibility and availability. Because women
born in the late 1940s are likely to have had more limited
educational opportunities than subsequent generations,
and because many of them are long-term residents of
recently gentrified suburbs, we chose to prioritise the stratification of participant education levels in our recruitment
strategy. Potential participants with a personal history of
breast cancer (themselves or close family member) were
excluded through a screening interview, as were health
professionals and those working in breast cancer advocacy. Thirty-four women were recruited (table 1). The
juries were socially and culturally diverse, sampling was
skewed towards higher levels of socioeconomic advantage
and lower educational attainment than the average for
the Australian population (table 1). All jurors received a
modest honorarium in recognition of their participation
and contribution to jury processes and outcomes.
Procedures
Each jury commenced with an orientation session introducing the questions and the process, where written
consent was also obtained. Jury day 1 focused on interrogating the epidemiological evidence and understanding
Degeling C, et al. BMJ Open 2018;8:e021174. doi:10.1136/bmjopen-2017-021174

Table 1

Characteristics of jury participants
Jury 1
(n=18)

Jury 2
(n=16)

Age (years)
 Range

70–74

70–74

 Median

71.64

71.24

18

16

 High school

8

3

 Trade/diploma

7

9

 University degree

3

4

 Australian/New Zealand

9

7

 Southern/Eastern European

4

2

 Southeast Asian

1

1

 Northeast Asian

0

1

 Southern/Central Asian

0

1

 Northwest European

4

4

 Low

1

1

 Middle
 High

4
13

3
12

Gender
 Female
Highest educational attainment

Cultural background/ethnicity*

Socioeconomic status of suburb†

*Based on Australian Standard Classification of Cultural and Ethnic
Groups.
†Based on Socioeconomic Index for Area.

basic cancer biology and common clinical and practical
issues (table 2). Testimony from four experts was prerecorded and shown to jurors as video presentations.
Experts were selected on the basis of their institutional
roles, experience and expertise, to provide balanced and
factual information and the best case ‘for’ and ‘against’
continuing to invite women their age. The expert presentations covered: (1) the varied nature and incidence of
breast cancer, and common clinical care pathways and
treatment outcomes in Australia; (2) the concept of
overdiagnosis and the difficulties of evaluating the value
of mammography screening for individuals and populations and (3) opposing perspectives on the efficacy
and potential impacts of including women their age in
mammography screening programmes (table 2). Each
presentation ran for approximately 20 min. Prerecording
ensured the format of the evidence presented was standardised across juries. Each expert’s biosketch and the
video presentations shown to the juries are available
online.24
After each expert’s video was screened, we opened
a conference call between that expert and the jurors
for questioning. Facilitated by a researcher, these
question and answer sessions allowed jurors to clarify
or challenge the arguments presented, ask further
questions, and raise and discuss practical and clinical
3
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Expertise

Expert area

1

Public health and breast
physician

Senior clinical consultant—
breast cancer screening and
diagnostics (imaging).

2

Clinical epidemiology and
family medicine (general
practice)

3

Cancer control and cancer
service management

4

Medical epidemiology,
clinical trial design,
execution and analysis

(1) Review of breast cancer biology, epidemiology and
mortality for women in Australia.
(2) A detailed description of current approaches to breast
cancer screening, common diagnostic and treatment
pathways, and their outcomes for Australian women aged
70–74.
Screening evaluation, clinical (1) Review of the benefits and harms of population screening
guidelines and overdiagnosis. (and how the balance between them changes with age).
(2) The nature of overdiagnosis, overtreatment and their
relationship to population screening programmes.
(3) The importance and limitations of evidence in making
decisions about screening.
Healthcare administration,
(1) Their expert opinion as to likely impacts and implications
cancer primary prevention and of ceasing to invite women aged 70–74 to participate in
palliative care.
mammography screening.
(2) The most compelling and important reasons for
continuing to invite women aged 70–74 to participate in
screening mammography.
Women’s health epidemiology. (1) Their expert opinion as to likely impacts and implications
of continuing to invite women aged 70–74 to participant in
mammography screening.
(2) The most compelling and important reasons for ceasing
to invite women aged 70–74 to participate in screening
mammography.

issues that were important to them. Participants asked
the experts their individual questions directly via telephone, following a brief preparatory discussion among
the group. At the end of the interaction with each
expert witness, jurors were asked whether they were
satisfied or had further questions. Because new issues
can emerge and gain importance to jurors during the
course of a citizens’ jury, expert witnesses remained
available via email to answer any further questions
that arose during subsequent proceedings. Facilitation
focused on promoting constructive dialogue and fair
interaction among jurors.
For the first hour and a half of jury day 2, jurors
reflected on, discussed and debated the evidence,
aided by a researcher acting as facilitator. Juries then
deliberated for an hour without researchers present to
come to a majority verdict on the questions posed and
a set of recommendations. The verdict, underpinning
reasoning and dissenting views were reported to the
research team in a final facilitated feedback session.
Data collection and analysis
The unit of analysis in this study is the deliberative group
(jury). All jury deliberations (facilitated and unfacilitated) and expert question and answer sessions were
audio recorded and transcribed. Previous research
indicates that Australian women are generally enthusiastic about screening but have minimal awareness about
overdiagnosis.25 26 In our previously reported trial of a
decision aid about whether to continue or stop screening
among women aged 70 years, 78% reported a positive
4

Data provided

intention to continue screening at baseline.27 To track
changes in the positions held by individual jurors,
participants completed an anonymous ballot at three
time points during jury proceedings (after they had
been presented all the evidence at the conclusion of
day 1; after they had had time to consider this evidence
overnight at the beginning of day 2 and after the deliberation and delivery of the verdict at the end of day 2).
Jurors also completed an Exit Survey for the purposes
of process evaluation at the very end of the final jury
session. During the final session of each jury, the verdict
and reasons were recorded by a researcher on a flipchart.
Each point was reviewed by the jury to ensure accuracy.
Jury transcripts were subsequently reviewed to further
explore and clarify the key reasons why jurors supported
or rejected the presented options. In what follows we
have summarised jurors’ own descriptions of the rationale and reasoning that underpins their responses to
the question asked of them. In analysis of all the data
collected, the differences between lay perspectives and
those held by epidemiologists came into sharp focus
and showed the challenges of changing how screening
services are targeted and organised, and of communicating about screening risks, including overdiagnosis.
For reasons of space in this paper, we will report only on
the jurors’ response to PART A (figure 1). The response
of the jurors to PART B, and a more detailed analysis of
the values and priorities revealed during their deliberations will be reported elsewhere.
Degeling C, et al. BMJ Open 2018;8:e021174. doi:10.1136/bmjopen-2017-021174
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Table 2 Expert testimony provided to the community juries
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Citizens’ jury 1:
16 voted to
continue inviting
2 voted to stop
inviting
CJ1

Citizens’ jury 2:
10 voted to
continue inviting
6 voted to stop
inviting
CJ2

For/
against continuing

For/
against continuing

Ballot after
evidence

15–3

9– 7

Ballot after
overnight break
Ballot at end of
process

16–2

10–6

16–2

10–6

Time point

Patient and public involvement
Research question development was informed by our
previous work with Australian women exploring their
attitudes to screening and understanding of the concept
of overdiagnosis.25–27 Patients or members of the public
were not involved in study design or recruitment. Study
results will be disseminated to participating member
of the public through providing them with a one-page
summary and copies of published reports.
Results
Both juries reported a majority verdict that BreastScreen
Australia should continue to invite women 70–74 to
participate in the government-funded breast screening
programme and promote participation to this age group.
Table 3 shows that this position was more strongly held
by jury 1 than Jury 2. Even though the overall balance
of votes remained fairly stable during the course of both
juries, analysis of the three time point ballots indicates
that several participants changed their positions during
jury proceedings (three in jury 1 and five in jury 2).
Although some individuals changed their position, the
overall majority position of the groups did not change.
This is because individuals shifted in both directions—
towards and away from supporting screening (table 3).
The results of the Exit Surveys support our impression
that all of the jurors were confident in their interactions
with each other and the experts. Transcripts of questions
and discussions during proceedings indicate that over the
course of the jury proceedings the vast majority of the
jurors comprehended concepts being discussed and that
all of them understood the trade-offs implicit in the question we were asking them to address during their deliberations. While we avoided formally ‘testing’ participants
so as not to intimidate them, the Exit Surveys for both
juries show that all participants believed that the process
was fair and that they had sufficient understanding of
the evidence presented to discuss the issues important to
them and come to a final decision. Table 4 illustrates the
Degeling C, et al. BMJ Open 2018;8:e021174. doi:10.1136/bmjopen-2017-021174

range of ways in which jurors justified their positions. The
key reasons jurors gave for their decision are as follows:
Reasons to continue inviting
Being invited to be screened has symbolic importance
Many jurors said that extending the invitation to participate in screening to older women showed that society still
cared about them. The invitations demonstrated ongoing
investment in maintaining the health of older women.
This relied on arguments that breast cancer remained
relevant in this group (older women could still get a fatal
breast cancer), arguments about life expectancy and
arguments about the function of an invitation.
Health professionals cautious about screening in this
age group argue that these women’s life expectancy is too
short for them to benefit from screening. Women who
said screening was symbolically important rejected the
life expectancy argument, for two reasons: (1) average
life expectancy was increasing; (2) some women lived
much longer than average. Using average life expectancy
to limit resources for early breast cancer detection was
therefore seen as unfairly discriminatory. As a participant
in jury 1 noted:
Today a 70-year-old still has a lot to contribute to a society and needs opportunity to live a full and healthy
life as any other citizen.
In the ‘symbolic importance’ view, invitations had a
certain function: they signified a respect/recognition
that older women mattered, ensuring that women who
wanted to continue to participate in screening knew they
were still eligible. The invitation allowed women to decide
for themselves if they still wanted information about their
breast cancer status, and receive reassurance that they
remained cancer free.
Screening is different from treatment
As indicated above, most participants held that receiving
more knowledge about their health was beneficial, and
saw screening simply as a source of such knowledge,
enabling choice. It was good for a woman to know if she
had breast cancer, even if the potential consequences
were extremely uncertain. The jury process was crafted
to ensure jurors understood the extent and significance
of this uncertainty. Nonetheless, many jurors insisted that
the problem was not the information from screening, but
the side effects of treatment that followed for a breast
cancer that would not have caused harm. Speaking on
behalf of the majority position, a juror from jury 2 said:
…over-diagnosis, it’s the wrong expression. It skews
the research in the wrong direction… collecting
knowledge is not harmful, it’s what you do with it that
can cause harm.
Jurors acknowledged that the potential for screening
to cause unnecessary harms was a highly significant
issue, but were unconvinced this should restrict
opportunities for individuals to receive information
5
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Reasons to continue inviting
 1. Being invited has symbolic importance
  Jury 1

If I get a reminder, it just gives me a little bit, um, more authority to go in and say, I’ve been invited, more
confidence to go in and say—I know it’s just emotional because I could just walk in and say, I want to be,
you know, I want you to put me back on your roll, but it’s just nice to know that I’ m still there and I’m getting
an invitation.

  Jury 2

If something which was offered for 20 years and suddenly it stops, it just has this connotation of I don’t
matter anymore. Invitation doesn’t mean that it is mandatory.

 2. Screening is different to treatment
  Jury 1

It’s up to you then whether you want to go ahead with the treatment, and I’m not one to bury my head in the
sand and say, ‘Oh, what I don't know doesn’t hurt me.’ I would rather know and then it’s my choice to have it
treated or not treated.

  Jury 2

It’s not the screening… it’s the treatment what does the harm. And I think that the problem with the
semantics here, right? How picking up more information which you really can do now because that
screening is more effective, it’s harmful, it’s harmful what we do after.

 3. There is too much uncertainty to arrive at a definitive answer
  Jury 1

I think it’s a retrograde step because we haven’t had enough Australian studies to justify going backwards
yet. I would like to see more Australian studies to have a better argument for saying let’s go back

  Jury 2

I just feel like, wow, this is—I went home last night and I felt like, you know, I was going to avoid …, it
comes down to your interpretation of this. Some of the others might say that was very good, someone else
would say negatively, well, you know, pretty ordinary. So it’s hard to have a definitive answer to the question
because the evidence is unclear.

Reasons to stop inviting
 1. Iatrogenic harms
  Jury 1

So we’ve got a range of reasons. We’ve got we might be making people anxious, such that it’s not worth it.
We’ve got that we might be harming people, um, and it might be more important to focus on quality of life
rather than potentially harming them.

  Jury 2

I think that seems to me that overdiagnosis causes more trouble than no diagnosis at all, um, more harm is
caused through overtreatment of cancer than—that are never going to cause any problems to people in the
long-run anyway.

 2. The shock of cancer heterogeneity
  Jury 1

So it is not saving lives, which fascinates me. Because that’s why I had mammograms, because I was
wanting early detection. I wanted to have a longer life. But what you are all saying, except those who are
voting to stop, um, is that you want to live longer and you want to have quality of life and you— you want
to—to be valued and you want all that as, of course, I do, but screening is not going to make a difference to
that.

  Jury 2

…The thing that really struck me yesterday was not all breast cancer is a death sentence and I don’t think
enough women know that. I still hear women say, oh well, I don’t want to have a mammogram or, um, smear
tests or anything because I don’t want to find out if I have it, and I think if it were made clearer for women to
know there are some cancers that are not a death sentence, you’ll probably die of something else.

 3. Opportunity costs
  Jury 1

  Jury 2

It is a fact that screening costs money and so we could allocate that money to screening, we could allocate
it to something else. And I think this point against is actually screening is not a very good investment overall
and we could get more value from investing that money in, say, breast cancer research.
I would like to just bring up the fact about costs. I mean, some people might take it personally that, oh
well, you know, we’re a forgotten age, which in some ways I agree. But I’m also practical and there’s only
so much money in the health bucket. Now, you know, breast cancer gets a lots of publicity, it has a lot of
charities, so to breast cancer, and I think because of that and all that publicity more women have had their
screening, they’ve had, um, treatment for their breast cancers, but there are so many other different cancers
and other terrible conditions where there’s hardly any money, there’s hardly any research being spent on
that.

and make choices. Instead, medical professionals
should improve the guidance they provided to
women diagnosed through screening, and should
6

tailor a woman’s treatment, if any, according to their
preferences, profile of comorbidities and specific
circumstances.
Degeling C, et al. BMJ Open 2018;8:e021174. doi:10.1136/bmjopen-2017-021174
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Table 4 Examples of reasons participants gave for and against proposed actions
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Reasons to stop inviting
Iatrogenic harms
The key reason given for the minority position was the
potential for unnecessary iatrogenic harms and in particular the risk of overtreatment. Participants who took this
position in both juries gave great significance to evidence
that pre-existing conditions such as heart disease and
preclinical cognitive disorders (which may be unknown to
the individual affected) can interact with and compound
the harms of standard breast cancer treatments.
The shock of cancer heterogeneity
Almost all of the jurors were surprised to learn that not
all breast cancers inevitably cause morbidity and mortality
if left untreated. This is consistent with previous studies
of public awareness around cancer overdiagnosis.28 29 For
jurors who voted against continuing to invite women,
the possibility that many cancers picked up by screening
were harmless undermined the value of early detection,
especially as modern treatments mean that those with
more advanced disease are now able to be treated more
effectively.
Opportunity costs
Some women, thus, argued that money spent on offering
organised screening to women aged 70–74 would be
better spent on breast cancer research. These women also
tended to endorse the proposal put forward by expert 4
that clinical examination was a more trustworthy means
of detection in older women.
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Discussion
After 2 days of information and deliberation, the majority
of both juries voted to continue to send invitations and
promote participation in mammography screening to
women aged 70–74. Neither jury was unanimous in their
vote, consistent with previous studies indicating that
women’s responses to information about the relationship
between mammography screening and overdiagnosis are
diverse.25 30 Participants’ responses reflected a central
conceptual problem in reasoning about screening. Both
the mortality benefit and the harm of overdiagnosis and
overtreatment—at least in breast cancer—can only be
seen at the level of populations, so there is always uncertainty as to which individuals benefit from participation
and which are harmed. Nevertheless, the majority of
participants in both juries maintained that an opportunity to detect a potentially fatal breast cancer early was
highly important. In their deliberations, several jurors
argued that even imperfect information could assist
women to make their own choices. Notably, however,
during the reporting of the verdicts jurors also sought
to emphasise that their support for this position was
amenable to change. Many jurors who voted to continue
to invite women now said if the current UK age extension
trial found definitive evidence of significant harms from
screening participation they might alter their position.7
Possible limitations to this study include: (1) the small
size of the groups and (2) the relatively high socioeconomic status of the residential areas from which participants came. With respect to group size, however, we note
that this is an inevitable characteristic of jury research.
Community juries are composed of small groups of
‘engaged citizens’. Community juries are designed to
promote participant inclusivity and deliberative participation rather than achieve statistical representation.
Juries are typically composed of a manageable number
of people (12–15) to ensure the quality of participation
and deliberation: in larger groups it is difficult to ensure
quality of process. The constitution of these juries was
in fact a strength. While most of the participants lived
in areas of relative socioeconomic advantage, the rapid
gentrification of some areas of Sydney make this sociodemographic distinction difficult to interpret for older
age groups. We paid close attention, through participant
screening, to obtaining a socially and culturally diverse
sample. Because two juries came to similar conclusions
underpinned by similar reasoning, it seems likely our
findings are replicable.
A possible limitation is the absence of expert testimony
from patients with breast cancer or survivors. However,
because all of the expert witnesses have previously occupied or continue to occupy relevant clinical roles, they
were able to reflect and comment on the more personal
aspects of breast cancer diagnosis and care in response to
jurors’ questions and discussions. A strength of this study
was the quality and reputation of the experts who gave
testimony, and the process by which they moderated one
7
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There is too much uncertainty to arrive at a definitive answer
Finally, participants in both juries found arriving at a
decision difficult because of the types and levels of uncertainty surrounding the evidence. Key concerns for jurors
included:
►► That there was no guarantee that an apparently indolent cancer would not become life threatening at a
later stage.
►► That the cut-off ages for screening target groups are
based on out-of-date demographic data that do not
reflect recent shifts towards longer life expectancy.
►► That environments are increasingly carcinogenic and
therefore we cannot know what the future risk is for
people living now.
►► That once defunded, it would be difficult to reinstate
the programme as the money would be allocated
elsewhere.
For these reasons, jurors argued that decision-makers
should be cautious about limiting opportunities for early
detection. This was because they ascribed a broader set of
benefits to screening invitations and participation than
those commonly recognised by epidemiologists. Invitations to women in this age group, they argued, should
cease only when the evidence of an adverse balance of
harms to benefits is solid and not contested by experts.

Open access

8

Conclusion
In the face of expert disagreement, members of the public
may have a strong preference to continue to receive interventions that give them information about their health
(however uncertain). Older women, even those who have
been informed in detail of the potential benefits and
harms of screening participation, may highly value early
detection programmes, seeing the invitation to screening
as an opportunity for choice and a demonstration that
society continues to recognise and invest in them. Current
arguments for withdrawal of breast screening because
of harms associated with overdiagnosis in people with
reduced life expectancy seem unlikely to resonate with
older women. This study suggests that broader cultural
values will need to be addressed if cancer screening is to
be de-intensified or de-implemented because of epidemiological evidence of harm.
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another’s presentations until all experts could accept that
all views presented could be argued from the evidence.
Breast cancer is an emotive subject with a high public
profile and most people have direct experience of loved
ones affected by the disease. Consistent with recent
findings from the USA and UK, most jurors were and
remained enthusiastic about screening and rejected
the use of average life expectancy to decide screening
programme exit points.28 31 32 They did not find statements about overdiagnosis to be persuasive or important
to their decision-making about screening participation.32 33 For many jurors, being invited to participate in
screening programmes validated their continued worth
to society; they deserved the same opportunities to maintain their health as younger people. To remove services
on the basis of projected life expectancy was seen as being
fundamentally ageist and entirely unjust.
Importantly, the reasons given by jurors diverged from
those often debated in the epidemiological and clinical
literature on the pros and cons of breast cancer screening.
Jurors were less concerned with consequences, and utilitarian calculations of the balance between benefits and
harms, or estimates of net benefit. They focused more
on other attributes of moral good, such as the protection
of an individual’s right to choose and recognition of the
value of individual lives.34 Moreover, the results of our
research stand in contrast to a citizens’ jury held in New
Zealand composed of women who had yet to commence
screening, after the cut-off for programme entry was
lowered to 45 years.21 The jury of women aged 40–49 was
asked: Should the New Zealand government offer free
screening mammography to all women aged 40–49 years?
Participants were unanimously in favour before the jury,
but voted 10–1 against after. The balance of harms and
benefits is different between women 40–49 and 70–74.
However, we speculate that the difference in outcome
between the two studies may arise in part from strong
personal investment in the value of breast screening
because of past participation.25 33
Our study has significant implications for those advocating for extending or de-implementing screening
services to older target groups. The balance of benefits
and harms from screening is often finely balanced, when
viewed from the perspective of guidelines committees
(or individuals) adopting an evidence-based approach to
utility assessment. As our results show, once a screening
programme becomes socially and culturally embedded
it may develop significant symbolic value. Epidemiologically evidenced, population-based information about
potential benefits and harms of participation does not
appear to resonate sufficiently with many women so as to
lead them to reassess the symbolic and personal values
and meanings they ascribe to screening.33 34 Consequently, any changes in the organisation of mammography screening need to be strongly founded in evidence,
but are also likely to require greater-than-usual transparency and engagement with other relevant community
values.35
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